Abpro submits IND to FDA for phase 1 trial of ABP-102/CT-P72 in HER2+ cancers

Abpro Holdings, Inc.

IND filed for ABP-102/CT-P72, a HER2×CD3 T cell engager targeting HER2-positive solid tumors.
Co-developed with Celltrion; phase 1 start expected in 1H 2026 pending FDA clearance.
Preclinical data presented at AACR 2025 and SITC 2025 showed selective activity in HER2-high tumor models.
First IND submission by Abpro for a solid tumor indication, advancing its immuno-oncology pipeline.
Phase 1 study will evaluate safety, PK, and preliminary efficacy in dose-escalation and expansion cohorts.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.